Related references
Note: Only part of the references are listed.Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention
Sheetal Parida et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2014)
Acute and sub-chronic toxicity studies of the extract of Thunberg Fritillary Bulb
Zehui Li et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2014)
Oral 4-week and 13-week toxicity studies of polyvinyl acetate vinyl laurate copolymer in rats
Horst Messinger et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2014)
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling
B. N. Prashanth Kumar et al.
BMC CANCER (2013)
The Multiple Faces of Prostaglandin E2 G-Protein Coupled Receptor Signaling during the Dendritic Cell Life Cycle
Sandra De Keijzer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer
Shashi Rajput et al.
PLOS ONE (2013)
Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: Safety profiling
Utpal Nandi et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2013)
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
Xinrong Ma et al.
ONCOIMMUNOLOGY (2013)
The Prostanoid EP4 Receptor and Its Signaling Pathway
Utako Yokoyama et al.
PHARMACOLOGICAL REVIEWS (2013)
EP4 receptors mediate prostaglandin E2, tumour necrosis factor alpha and interleukin 1 beta-induced ion secretion in human and mouse colon mucosa
Sian E. Fairbrother et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Involvement of COX-2/PGE2 signalling in hypoxia-induced angiogenic response in endothelial cells
Lixing Zhao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model
Xiping Xin et al.
LABORATORY INVESTIGATION (2012)
Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Kieran Clarke et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2012)
Prostaglandins and Inflammation
Emanuela Ricciotti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
Jocelyn Reader et al.
CANCER AND METASTASIS REVIEWS (2011)
The COX-2/PGE(2) pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Alexander Greenhough et al.
CARCINOGENESIS (2009)
Functional Selectivity of Natural and Synthetic Prostaglandin EP4 Receptor Ligands
Martin Leduc et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
EP4 and EP2 receptor subtypes involved in colonic secretion in rat
Ahmed Soliman Mosa et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2008)
GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyllacetyl} benzene sulphonamide):: a novel, potent and selective prostanoid EP4 receptor antagonist
Richard J. Wilson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Targeting prostaglandin E EP receptors to inhibit metastasis
Amy M. Fulton et al.
CANCER RESEARCH (2006)
Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention
AJ Dannenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
GP Pidgeon et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
